Search Results - "Boulton, D. W."

Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin by Kasichayanula, S., Liu, X., Griffen, S. C., LaCreta, F. P., Boulton, D. W.

“…Aims Dapagliflozin is a selective sodium glucose cotransporter 2 (SGLT2) inhibitor that decreases serum glucose by reducing renal glucose reabsorption, thereby…”
Get full text

Evaluation of 4β‐Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism–Based Pharmacometric Model by Leil, TA, Kasichayanula, S, Boulton, DW, LaCreta, F

“…A Bayesian mechanism–based pharmacokinetic/pharmacodynamic model of cytochrome P450 3A4 (CYP3A4) activity was developed based on a clinical study of the…”
Get full text

Lack of a pharmacokinetic drug-drug interaction between lithium and valproate when co-administered with aripiprazole by Boulton, D. W., Kollia, G. D., Mallikaarjun, S., Kornhauser, D. M.

“…Summary What is known and Objective:  The antipsychotic, aripiprazole, plus lithium or valproate demonstrates rapid and significant improvement in manic…”
Get full text

The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder by Boulton, DW, Balch, AH, Royzman, K., Patel, CG, Berman, RM, Mallikaarjun, S., Reeves, RA

“…Possible effects of the atypical antipsychotic aripiprazole on the pharmacokinetics of standard antidepressant therapies (ADTs) were assessed in two…”
Get full text

Fate of the Flavonoid Quercetin in Human Cell Lines: Chemical Instability and Metabolism by BOULTON, DAVID W., WALLE, U. KRISTINA, WALLE, THOMAS

“…Although cell cultures are increasingly being used as models for studying the biological actions of flavonoids, no information on the fate, such as uptake and…”
Get full text

A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3‐O‐glucuronide in Renal or Hepatic Impairment by Walt, J‐S, Hong, Y, Zhang, L, Pfister, M, Boulton, DW, Karlsson, MO

“…Dapagliflozin is a sodium–glucose co‐transporter 2 inhibitor in development for the treatment of type 2 diabetes mellitus. A semi‐mechanistic population…”
Get full text

Effect of St. John's wort ( Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers by Markowitz, J.S., DeVane, C.L., Boulton, D.W., Carson, S.W., Nahas, Z., Risch, S.C.

“…The effects of the herb St. John's wort ( Hypericum perforatum), a purported antidepressant, on the activity of cytochrome P-450 (CYP) 2D6 and 3 A4 was…”
Get full text

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus by Kasichayanula, S, Chang, M, Hasegawa, M, Liu, X, Yamahira, N, LaCreta, F.P, Imai, Y, Boulton, D.W

“…Aims: Dapagliflozin, a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2) is in development for the treatment of type…”
Get full text

Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus by Tang, W., Leil, T. A., Johnsson, E., Boulton, D. W., LaCreta, F.

“…Aims To compare the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 diabetes mellitus (T1DM) versus type 2 diabetes mellitus…”
Get full text

Enantioselective disposition of salbutamol in man following oral and intravenous administration by BOULTON, D. W., FAWCETT, J. P.

“…1 Salbutamol is a β2,‐adrenoceptor stimulant used clinically as a racemate where the activity resides predominantly in the (‐)R enantiomer with little or no…”
Get full text

Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus by Tirucherai, G. S., LaCreta, F., Ismat, F. A., Tang, W., Boulton, D. W.

“…Aims To evaluate the pharmacokinetic (PK)/pharmacodynamic (PD) and safety profile of dapagliflozin in paediatric patients aged 10–17 years with type 2 diabetes…”
Get full text

Extensive Binding of the Bioflavonoid Quercetin to Human Plasma Proteins by BOULTON, DAVID W., WALLE, U. KRISTINA, WALLE, THOMAS

“…Although the bioflavonoids, a large group of polyphenolic natural products, exert chemopreventive effects in cardiovascular disease and cancer, there is little…”
Get full text

Comparison of the exposure-response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus by Parkinson, J., Tang, W., Johansson, C-C., Boulton, D. W., Hamrén, B.

“…Aims To quantitatively compare the exposure–response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus (T2DM) and to…”
Get full text

Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects by Kasichayanula, S, Liu, X, Shyu, W.C, Zhang, W, Pfister, M, Griffen, S.C, Li, T, LaCreta, F.P, Boulton, D.W

“…Aims: Dapagliflozin increases urinary glucose excretion by selectively inhibiting renal sodium-glucose transporter 2, an insulin-independent mechanism of…”
Get full text

The pharmacokinetics of levosalbutamol : What are the clinical implications? by BOULTON, David W, FAWCETT, J. Paul

“…Salbutamol (albuterol) is a beta2-adrenoceptor agonist used as a bronchodilator for the treatment of asthma and as a uterine relaxant for the suspension of…”
Get full text

Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects by Kasichayanula, S., Liu, X., Zhang, W., Pfister, M., Reele, S. B., Aubry, A.-F., LaCreta, F. P., Boulton, D. W.

“…Dapagliflozin is a potent and selective inhibitor of sodium–glucose co‐transporter type 2 that is being developed for the treatment of type 2 diabetes…”
Get full text

Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects by Patel, C. G., Kornhauser, D., Vachharajani, N., Komoroski, B., Brenner, E., Handschuh del Corral, M., Li, L., Boulton, D. W.

“…Aim: To evaluate the pharmacokinetic interactions of the potent, selective, dipeptidyl peptidase‐4 inhibitor, saxagliptin, in combination with metformin,…”
Get full text

Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen®, a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women by Upreti, V. V., Hsiang, C. B., Li, L., Xu, X., LaCreta, F. P., Boulton, D. W.

“…Saxagliptin (Onglyza™) is a dipeptidyl peptidase‐4 (DPP4) inhibitor for treating type 2 diabetes mellitus. This open‐label, randomized, two‐way crossover study…”
Get full text

Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans by BOULTON, D. W, FAWCETT, J. P

“…Albuterol (INN, salbutamol) is a beta 2-adrenergic receptor agonist widely used in the treatment of asthma. It is administered clinically as a racemic mixture,…”
Get full text

Disposition of Morphine in Tissues of the Pregnant Rat and Foetus Following Single and Continuous Intraperitoneal Administration to the Mother by DEVANE, C. L., SIMPKINS, J. W., BOULTON, D. W., LAIZURE, S. C., MILLER, R. L.

“…Foetal exposure to maternally administered opiates such as morphine represent a serious human health problem but disposition studies in man are difficult to…”
Get full text